EGFR and non-small cell lung carcinoma: Osimertinib can potently inhibit both EGFR-TKI-sensitizing mutations (EGFRm) and EGFR T790M mutation and has been approved as the first-line therapy for advanced NSCLC patients with EGFR mutation in 2018 (4–6).